Help appealing denials for this cardiac myosin inhibitor for symptomatic obstructive HCM.

Appeal Your Myqorzo Denial

Don't let your insurer deny access to this first-in-class treatment for obstructive hypertrophic cardiomyopathy.

Start Your Appeal
Chat with AI Assistant

Understanding Your Myqorzo (aficamten) Denial

Myqorzo (aficamten) is a cardiac myosin inhibitor FDA-approved for adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) to improve functional capacity and symptoms. Insurance denials often cite lack of prior authorization, preference for older treatments, or questions about medical necessity. If your cardiologist prescribed Myqorzo, you have strong grounds for appeal.

Common Reasons for Denial

  • ! Not medically necessary
  • ! Prior authorization required
  • ! Preferred alternative available (mavacamten/Camzyos)
  • ! Insufficient documentation of oHCM diagnosis
  • ! Step therapy requirement not met
  • ! Specialty tier drug not covered

How We Help

We help you document your oHCM diagnosis, symptom severity, prior treatments, and why Myqorzo is the appropriate choice for your condition. Our AI-powered tool generates a compelling appeal letter citing clinical evidence.

Start your Myqorzo appeal — it takes about 3 minutes.

Some Types of Evidence We Can Use For Supporting Your Appeal

✓ Aficamten is a selective cardiac myosin inhibitor that reduces excessive contractility in obstructive HCM, improving symptoms and exercise capacity.

✓ Clinical trials demonstrated significant improvement in peak oxygen uptake and reduction in LVOT gradient with aficamten treatment.

✓ Obstructive HCM significantly impacts quality of life and can lead to heart failure, arrhythmias, and sudden cardiac death if inadequately treated.

✓ Current guidelines support the use of cardiac myosin inhibitors for patients with symptomatic oHCM who have inadequate response to or cannot tolerate beta-blockers or calcium channel blockers.

Patient Assistance & Copay Programs

These programs may help reduce your costs while you appeal:

MYQORZO & You Patient Support ↗

Cytokinetics patient support program offering insurance navigation, financial assistance for eligible patients, and disease education. Call 833-MYQORZO (833-697-6796).

Eligibility requirements and program terms may change. Please verify current details directly with each organization.

Patient Advocacy & Support Organizations

These organizations provide education, support, and advocacy for patients:

National Organization for Rare Disorders (NORD) ↗

Leading patient advocacy organization for rare disease community.

Global Genes ↗

Leading rare disease patient advocacy organization connecting and empowering patients.

Frequently Asked Questions

Common reasons include lack of prior authorization, insurer preference for other treatments, insufficient documentation of your oHCM diagnosis, or the drug being on a high-cost specialty tier. Your denial letter should specify the reason.

Helpful documentation includes your echocardiogram results showing LVOT obstruction, documentation of your symptoms (shortness of breath, chest pain, exercise intolerance), records of prior treatments tried, and a letter from your cardiologist explaining why Myqorzo is medically necessary.

Myqorzo is typically covered under Medicare Part D as a specialty pharmacy drug. However, prior authorization is usually required, and you may need to demonstrate that you meet specific clinical criteria for coverage.

Ready to Fight Your Myqorzo (aficamten) Denial?

Our free AI-powered tool will help you generate a compelling appeal letter in minutes.

Start Your Appeal Chat with AI Assistant

Disclaimer: Fight Health Insurance is not affiliated with, endorsed by, or partnered with any pharmaceutical manufacturer, healthcare provider, medical device company, or patient assistance program, including Cytokinetics. All information provided is for educational and informational purposes only and does not constitute medical or legal advice. Please consult with your healthcare provider regarding treatment options and with your insurance company regarding coverage decisions.